Additionally, by comparing overall survival of HCC patients in low and high MTX1 groups, we found that patients with high MTX1 expression had a worse prognosis after treatment with sorafenib (Figure 4C), suggesting that high expression of MTX1 in human HCC is involved in sorafenib resistance, consistent with the mouse experiment above. This evidence concerns the gene MTX1 and hepatocellular carcinoma.